Tonix Pharmaceuticals Holding (TNXP) Research & Development (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Research & Development for 16 years, with the latest figure at $19.4 million in Q2 2026.

• On a quarterly basis, Research & Development rose 79.45% year-over-year to $19.4 million in Q2 2026; TTM through Jun 2026 was $63.9 million, a 79.05% increase from a year earlier, with the FY2025 full-year figure at $44.5 million, up 11.29% from the prior year.
• Research & Development was $19.4 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $18.2 million in the prior quarter.
• The five-year high for Research & Development was $26.5 million in Q1 2023, with the low at $7.4 million in Q1 2025.
• Average Research & Development over 5 years is $16.1 million, with a median of $17.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Research & Development slumped 56.7% in 2024, then soared 144.93% in 2026.
• Over 5 years, Research & Development stood at $24.7 million in 2022, then slumped by 30.62% to $17.1 million in 2023, then sank by 51.54% to $8.3 million in 2024, then soared by 104.18% to $16.9 million in 2025, then gained by 14.62% to $19.4 million in 2026.
• The last three Research & Development figures came in at $19.4 million (Q2 2026), $18.2 million (Q1 2026), and $16.9 million (Q4 2025), per Business Quant data.